読み込み中
DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients. In addition to DM199, the company is also developing DM300, which is in its pre-clinical stage for the treatment of various inflammatory conditions. Founded in 2000 and headquartered in Minneapolis, Minnesota, the company was previously known as DiaMedica Inc. before adopting its current name, DiaMedica Therapeutics Inc., in December 2016.
通常取引
$8.1703
+$0.1603 · +2.00%
日中の時刻はETです。市場データは遅延する場合があります。
DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients. In addition to DM199, the company is also developing DM300, which is in its pre-clinical stage for the treatment of various inflammatory conditions. Founded in 2000 and headquartered in Minneapolis, Minnesota, the company was previously known as DiaMedica Inc. before adopting its current name, DiaMedica Therapeutics Inc., in December 2016.
日中レンジ
現在 $8.1703
52週レンジ
現在 $8.1703
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
32
割高
センチメント
44
まちまち
リスク
56
やや高いリスク
モメンタム
54
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients. In addition to DM199, the company is also developing DM300, which is in its pre-clinical stage for the treatment of various inflammatory conditions. Founded in 2000 and headquartered in Minneapolis, Minnesota, the company was previously known as DiaMedica Inc. before adopting its current name, DiaMedica Therapeutics Inc., in December 2016.
日中レンジ
現在 $8.1703
52週レンジ
現在 $8.1703
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 研究開発 | 2461.4万 USD | 1905.7万 USD | 1311万 USD | 783.9万 USD | 876.5万 USD |
| 販売・一般管理 | 978.3万 USD | 762.4万 USD | 815.7万 USD | 616.2万 USD | 488.1万 USD |
| 営業費用 | 3439.7万 USD | 2668.1万 USD | 2126.7万 USD | 1400.1万 USD | 1364.6万 USD |
| 受取利息 | — | 230.1万 USD | — | — | — |
| 減価償却費と償却費 | 4.3万 USD | 3.9万 USD | 3万 USD | 2.5万 USD | 2.4万 USD |
| 営業利益 | −3439.7万 USD | −2668.1万 USD | −2126.7万 USD | −1400.1万 USD | −1364.6万 USD |
| 純利益 | −3276.6万 USD | −2444.4万 USD | −1938.1万 USD | −1367.6万 USD | −1359.2万 USD |
会社概要が更新されました 2026年10月9日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$8.33
上昇余地（1.95%）この株式へのエクスポージャーを報告している上場投資信託です。
iShares Russell 2000 ETFIWM763.97万0.01%776.97億 USD0.19%$278.95+0.50%
iShares Russell 2000 Growth ETFIWO274.6万0.02%140.44億 USD0.24%$356.78+0.94%
Vanguard Extended Market ETFVXF228.95万0.00%954億 USD0.05%$234.81+0.72%
Vanguard Russell 2000 ETFVTWO133.27万0.01%180億 USD0.06%$112.68+0.51%
iShares Micro-Cap ETFIWC91.94万0.07%13.19億 USD0.60%$183.11+0.18%
Vanguard Russell 2000 Growth ETFVTWG25.73万0.01%17億 USD0.06%$260.49+0.91%
iShares Russell 2500 ETFSMMD16.08万0.00%40.01億 USD0.23%$86.32+0.42%
Global X - Russell 2000 ETFRSSL14.1万0.01%14.09億 USD0.08%$109.14+0.25%iShares Russell 2000 ETFIWMiShares Russell 2000 Growth ETFIWOVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCVanguard Russell 2000 Growth ETFVTWGiShares Russell 2500 ETFSMMDGlobal X - Russell 2000 ETFRSSLAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
